Inotuzumab ozogamicin

Drug Profile

Inotuzumab ozogamicin

Alternative Names: Besponsa; CMC-544; PF-5208773; WAY-207294

Latest Information Update: 27 Apr 2017

Price : $50

At a glance

  • Originator UCB
  • Developer Cancer Research UK; Children's Oncology Group; National Cancer Institute (USA); Pfizer; SWOG; University College London; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Cytostatic antibiotics; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action CD22 antigen inhibitors; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute lymphoblastic leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Acute lymphoblastic leukaemia
  • Phase I/II Chronic myeloid leukaemia
  • Phase I Burkitt's lymphoma
  • Discontinued Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma

Most Recent Events

  • 21 Apr 2017 Committee for Medicinal Products for Human Use (CHMP) of the EMA recommends approval of Inotuzumab ozogamicin for Acute lymphoblastic leukaemia (Second-line therapy or greater) in European Union
  • 08 Apr 2017 Case Comprehensive Cancer Center plans a phase I/II trial for Acute lymphoblastic leukaemia (In adolescents, In adults, In elderly) in USA (NCT03104491)
  • 31 Mar 2017 M.D. Anderson Cancer Center and Pfizer plan a phase II trial for Acute lymphocytic leukaemia (Refractory metastatic disease) in USA (NCT03094611)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top